On February 3, 2022 MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, reported that the Company’s management will participate in the following virtual conferences in February 2022 (Press release, MacroGenics, FEB 3, 2022, View Source [SID1234607685]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Guggenheim Healthcare Talks | 2022 Oncology Conference. MacroGenics’ management will participate in a fireside chat on Thursday, February 10, 2022, at 9:00 am ET. Management will also participate in one-on-one meetings.
Citi’s 2022 Virtual Immuno-Oncology Summit. MacroGenics’ management will participate in a fireside chat on Thursday, February 17, 2022, at 12:30 pm ET.
11th Annual SVB Leerink Global Healthcare Conference. MacroGenics’ management will participate in a fireside chat on Friday, February 18, 2022, at 10:40 am ET. Management will also participate in one-on-one meetings.
Webcasts of the above presentations may be accessed under "Events & Presentations" in the Investor Relations section of MacroGenics’ website at View Source The Company will maintain archived replays of these webcasts on its website for 30 days after each conference.